Exousia Pro Cancels 47M Dilutive Shares, Projects Significant Revenue from Telehealth Acquisitions
Summary
Exousia Pro, Inc. (MAJI) announced the strategic cancellation of derivative securities convertible into 47 million shares of common stock, effectively eliminating a massive source of future dilution. This was achieved via an exchange agreement involving 2 million LMMY shares. Concurrently, the company reported significant progress towards definitive agreements for three telehealth acquisitions, with one target entity already scaling monthly revenue from $80,000 to $135,000 and projecting a transformative $240,000 per month from a new exclusive supplier partnership. This news provides a strong counter-narrative to the recent 1-A POS filing on February 19, 2026, which outlined a highly dilutive Regulation A offering; the elimination of 47 million shares addresses a separate, even larger potential dilution event. The cancellation of such a substantial amount of potential dilution is a monumental positive for MAJI, given its micro-cap status, as it removes a significant overhang and de-risks the stock. The projected revenue from the telehealth acquisitions also represents a substantial and transformative increase in the company's financial outlook. Traders should monitor the finalization of the telehealth acquisition agreements, the company's planned share buyback program to neutralize Reg A dilution, and the outcome of the March 13th mediation for further share cancellations.
At the time of this announcement, MAJI was trading at $0.03 on OTC in the Life Sciences sector, with a market capitalization of approximately $1.4M. The 52-week trading range was $0.02 to $0.32. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.